Ian Bezek

Ian Bezek

InvestorPlace Contributor

Ian Bezek earned his economics degree from Colorado State University in 2010. He then worked as an analyst for Kerrisdale Capital, a New York City-based activist hedge fund, from 2011-13. Since then, Ian has focused on finding under-the-radar investment opportunities, particularly overseas. To that end, he taught himself Spanish and has lived in Mexico and Argentina among other countries. He currently resides in Colombia with his family.

You can interact with Ian on Twitter.

Recent Articles

Cardano Could Yield a Compelling Buy Opportunity on Its Broad Utility

By Ian Bezek, InvestorPlace Contributor

The price of ADA has dipped as traders fear that it is losing ground to Solana. That's true in the short run, but Cardano still has an opportunity.

Progenity: Don’t Bet on This Biotech Firm Yet

By Ian Bezek, InvestorPlace Contributor

PROG Stock IPOed in 2020 to develop a genetic testing business. Progenity has now shut that business down, leaving shareholders in a lurch.

AMC Enters in a Downtrend Following Disappointing Earnings

By Ian Bezek, InvestorPlace Contributor

AMC Entertainment just released another stinker of an earnings report. This is putting pressure on AMC stock as its financial situation worsens.

UiPath Is a Buy After Its Steep Decline

By Ian Bezek, InvestorPlace Contributor

PATH stock was arguably overpriced following its sizzling IPO. Now that the shares have cooled off, however, UiPath is worth a second look.

WHO’s Nod Can’t Mask Ocugen’s Flimsy Fundamentals

By Ian Bezek, InvestorPlace Contributor

Ocugen has been trying to commercialize a Covid-19 vaccine. However, many obstacles remain. Meanwhile, insiders are dumping OCGN stock.

Load More